Organization

daraxonrasib

13 articles

No recent mentions

Revolution Medicines Shows Major Advances in KRAS Inhibitors at AACR

Revolution Medicines revealed promising clinical trial results for their KRAS inhibitor in pancreatic cancer, more than doubling patient survival. The company also introduced a new catalytic inhibitor, indicating a breakthrough in cancer treatment research.

· 44d ago

Revolution Medicines' Pancreatic Cancer Drug Maintains Promising Results in Ongoing Trials

Revolution Medicines' drug daraxonrasib continues to demonstrate a median survival of 13.2 months in late-stage trials, consistent with earlier findings. The sustained results reinforce its potential to overhaul pancreatic cancer treatment approaches, pending further validation.

· 51d ago